Navigation Links
Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need
Date:7/19/2010

NEW YORK, July 19 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.

(Logo:  http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO )

The FDA's request follows further consideration of reports of adverse events in osteoarthritis patients taking tanezumab, and the agency's concerns regarding the potential for such events in other patient populations in which the compound is being studied.  Pfizer announced the suspension of tanezumab studies in patients with osteoarthritis in a June 23 press release.  

For studies on clinical hold, recruitment of new patients and the dosing of existing patients are suspended.  

Pfizer will continue to work with the FDA to reach a common understanding about the appropriate scope of continued clinical investigation of tanezumab.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.  We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.  Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.  Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  To learn more about our commitments, please visit us at www.pfizer.com.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer and SMC Collaborate on Liver Cancer
2. Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimers Association International Conference on Alzheimers Disease
3. Pfizer Inc and GoIndustry DoveBid Partner to Auction Surplus Equipment from R&D Facilities Across the United States
4. Pfizer Invites Public to View and Listen to Webcast of August 3 Conference Call With Analysts
5. Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg®
6. Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions
7. Pfizer Appoints Mikael Dolsten President of Worldwide Research and Development
8. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
9. Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot
10. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
11. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
(Date:5/9/2017)... 2017  Semler Scientific, Inc. (OTCQB: SMLR), an ... improve the clinical effectiveness and efficiency of healthcare ... quarter ended March 31, 2017. ... to identify when preventive care options are appropriate, ... heart attacks or strokes occur," said Doug ...
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 2017 , ... After raising nearly $30,000 on Kickstarter , about three-times ... at a discounted crowdfunding price on Indiegogo . , “Along with creating an ... to bring a fidget toy to the market that was made of superior quality ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a poignant ... of published author Laura Weigel Douglas, an avid reader who lives in the Pacific ... sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Water damage ... Lee, New Jersey School District had left education officials with a number of critical ... replacement of the flooring had to be accomplished with little or no disruption to ...
(Date:5/24/2017)... ... 24, 2017 , ... NucleusHealth ™, advancing clinical practice ... Food and Drug Administration (FDA) 510(k) clearance for its Nucleus.io ... for medical image management. At the core is patented streaming technology that provides ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well ... the ability to sell luxury homes anywhere on the planet. The luxury home market ... from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction will ...
Breaking Medicine News(10 mins):